Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - hydrocortisone sodium succinate, quantity: 133.7 mg (equivalent: hydrocortisone, qty 100 mg) - injection, powder for - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate - when oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, [invented name] powder for injection is indicated for intravenous or intramuscular use in the following conditions: 1. endocrine disorders ? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used). ? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful ? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected ? congenital adrenal hyperplasia ? nonsuppurative thyroiditis ? hypercalcaemia associated with cancer. 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: ? post-traumatic osteoarthritis ? synovitis of osteoarthritis ? rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) ? acute and subacute bursitis ? epicondylitis ? acute nonspecific tenosynovitis ? acute gouty arthritis ? psoriatic arthritis ? ankylosing spondylitis. 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: ? systemic lupus erythematosus ? systemic dermatomyositis (polymyositis) ? acute rheumatic carditis. 4. dermatological diseases ? pemphigus ? severe erythema multiforme (stevens-johnson syndrome) ? exfoliative dermatitis ? bullous dermatitis herpetiformis ? severe seborrhoeic dermatitis ? severe psoriasis ? mycosis fungoides. 5. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: ? bronchial asthma ? drug hypersensitivity reactions ? contact dermatitis ? urticarial transfusion reactions ? atopic dermatitis ? serum sickness ? acute noninfectious laryngeal oedema (adrenaline is the drug of first choice). 6. ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye, such as: ? herpes zoster ophthalmicus ? iritis, iridocyclitis ? chorioretinitis ? diffuse posterior uveitis and choroiditis ? optic neuritis ? sympathetic ophthalmia ? anterior segment inflammation ? allergic conjunctivitis ? allergic corneal marginal ulcers ? keratitis. 7. gastrointestinal diseases to tide the patient over a critical period of the disease in: ? ulcerative colitis (systemic therapy) ? regional enteritis (systemic therapy). 8. respiratory diseases ? symptomatic sarcoidosis ? loeffler?s syndrome not manageable by other means ? berylliosis ? fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy ? aspiration pneumonitis. 9. haematological disorders ? acquired (autoimmune) haemolytic anaemia ? erythroblastopenia (rbc anaemia) ? idiopathic thrombocytopenic purpura in adults (iv only; im administration is contraindicated) ? secondary thrombocytopenia in adults ? congenital (erythroid) hypoplastic anaemia. 10. neoplastic diseases for palliative management of: ? leukaemias and lymphomas in adults ? acute leukaemia in childhood. 11. oedematous states ? to induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus. 12. miscellaneous ? tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurological or myocardial involvement.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrocortisone, quantity: 20 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; macrogol 8000; lactose monohydrate; maize starch - indications as at 6 may 1992: hydrocortisone is indicated for replacement therapy in addison's disease or chronic adrenocortical insufficiency secondary to hypopituitarism.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrocortisone, quantity: 4 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; povidone - indications as at 6 may 1992: hydrocortisone is indicated for replacement therapy in addison's disease or chronic adrenocortical insufficiency secondary to hypopituitarism.

Kanada - Inggeris - Health Canada

teva canada limited - hydrocortisone (hydrocortisone sodium succinate) - powder for solution - 1g - hydrocortisone (hydrocortisone sodium succinate) 1g - adrenals

Kanada - Inggeris - Health Canada

teva canada limited - hydrocortisone (hydrocortisone sodium succinate) - powder for solution - 500mg - hydrocortisone (hydrocortisone sodium succinate) 500mg - adrenals

Kanada - Inggeris - Health Canada

teva canada limited - hydrocortisone (hydrocortisone sodium succinate) - powder for solution - 250mg - hydrocortisone (hydrocortisone sodium succinate) 250mg - adrenals

Kanada - Inggeris - Health Canada

teva canada limited - hydrocortisone (hydrocortisone sodium succinate) - powder for solution - 100mg - hydrocortisone (hydrocortisone sodium succinate) 100mg - adrenals

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 25 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

stat rx usa llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

physicians total care, inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus